OrbusNeich Receives Enterprise Asia Linchpin of Asia Award 2023 Commitment to Improving Patients’ Quality of Life Worldwide Continues to Gain Recognition

(Hong Kong, 31 July 2023) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, has been presented with the Enterprise Asia Linchpin of Asia Award 2023 in recognition of the Group’s leading position in the healthcare, pharmaceutical and biotechnology industry in Asia and its commitment to improving the quality of life of patients worldwide.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “We are honored to accept the prestigious Enterprise Asia Linchpin of Asia Award 2023. This award is a true testament to the unwavering dedication and hard work of our outstanding employees, who are spread across three continents and consistently demonstrate a strong commitment to excellence through their innovative solutions in endovascular intervention areas. This recognition inspires us to strive for even greater heights as we aim to broaden our product lines, enhance our R&D capabilities and expand our distribution network. Driven by our core values of Integrity, Passion, Innovation, and Performance, we will continue to strive to provide a variety of endovascular and structural heart interventional products to effectively improve patients’ quality of life worldwide.”

OrbusNeich is the first and only medical device company headquartered in Hong Kong Science Park to be listed on the Main Board of the Stock Exchange of Hong Kong and included as a constituent of the Hang Seng Composite Index and Stock Connect. The Group’s strong leadership team has extensive experience in the medical device industry and plans to continue to attract and retain top-tier talent to drive sustainable growth and innovation. With an illustrious history dating back to the turn of the millennium, OrbusNeich has steadfastly pursued its vision of improving the quality of life for vascular disease patients worldwide through pioneering technologies, never faltering in its mission to design and deliver innovative treatment solutions.

The Enterprise Asia Linchpin of Asia Award is a premier recognition program dedicated to honoring the best, brightest and most outstanding industry leaders and enterprises exclusively selected across Asia. The award honors the best business leaders and enterprises in Asia that have triumphed in the ever-changing business world and created success at the pinnacle of their respective industries, and provides them with the ideal platform for regional collaborations across 16 countries and 24 industries. The awardees are custodians of their own brands and champions of entrepreneurship and sustainability, and have made an impact in their industries and across the ecosystem. For more details, please refer to: https://apea.asia/linchpinofasiaawards/about-linchpin/

About OrbusNeich Medical Group Holdings Limited OrbusNeich is a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells products to over 70 countries and regions worldwide, and it is also the only PCI balloon manufacturer headquartered in China that ranked among the top 6 players in all major overseas PCI balloon markets including Japan (Ranked No. 2), Europe (Ranked No. 4), and the U.S. (Ranked No. 6) in terms of sales volume of PCI balloons in 2021 in accordance with the CIC Report. In addition, in terms of sales volume of PTA balloons in 2021, it ranked No. 3 in Japan and No. 4 in the U.S., respectively. It also specializes in coronary stent products and is actively expanding into neuro vascular intervention and structural heart disease areas. OrbusNeich owns more than 180 granted patents globally. Its in-house R&D team has over twenty years of product development experience and has developed proprietary, world leading technologies.